NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Atia Vision

Atia Vision

Private
Campbell, CaliforniaHealthcare & Life Scienceshttps://atiavision.com/

Last Round

Series E

Aug 2, 2022

Total Funding Raised

$85M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Atia Vision is a medical device company developing modular, shape-changing intraocular lens systems designed to restore dynamic range of vision for patients with cataracts and presbyopia.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Clinical Trials

Business Model

B2B

Customer Profile

Hardware Sales

AI Layer

Non-AI

Keywords

intraocular lensIOLcataract surgerypresbyopia treatmentshape-changing lensaccommodating IOLophthalmic devicevision restorationclinical trialsFDA approvalmedical technologyeye implantdynamic vision

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Atia Vision Comparables

Compare Atia Vision with similar companies based on industry and business-model similarity.

Atia Vision comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
LensGen
93%
Adaptilens
86%
AkkoLens International
83%

Atia Vision Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series EAug 2, 2022
Series DMay 2, 2019
Series CDec 10, 2018
Series CNov 9, 2018
Series BMay 1, 2015

Atia Vision Investors

Notable investors and investment history

Atia Vision investors
InvestorRounds
ShifamedSeries E, Series D
Cormorant Asset ManagementSeries E, Series D
ARTIS VenturesSeries B
The Capital PartnershipSeries E, Series D, Series C
PA MedTech VC FundSeries E
ShangBay CapitalSeries D
AMED VenturesSeries E, Series D

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 14, 2026

    Attended ASCRS to report on clinical trial results.

  • Apr 14, 2026

    Positive 36-month results for shape-changing IOL reported at ASCRS.

Atia Vision Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Atia Vision Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Atia Vision's valuation, stock price, and market status.

Firmographic Details

HeadquartersCampbell, California
Employee Range17
Year Founded2014
Last FundingAug 2, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.